GlassScriptPhysician profile
James Smelser
NPI 1881685089
$19,646.58
in general payments reported to CMS, 2019-2025
35 companies · $1,814 in 2025
The $1,814 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,600 · 2020: $2,991 · 2021: $3,269 · 2022: $721 · 2023: $1,273 · 2024: $1,979 · 2025: $1,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,998 · Education: $68.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,998.08 |
| Education | $68.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $11,857.34 | 2019-2023 | Aquadex Smartflow Console |
| Fresenius USA Marketing, INC. | $1,016.23 | 2019-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $921.66 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $883.29 | 2019-2024 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $871.87 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $562.89 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Calliditas Therapeutics US INC. | $535.52 | 2023-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $463.49 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $348.00 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $247.50 | 2021-2025 | |
| Ardelyx, INC. | $243.64 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Travere Therapeutics, INC. | $237.27 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $228.51 | 2024-2025 | Terlivaz |
| Glaxosmithkline, LLC. | $195.66 | 2021-2024 | Benlysta, Jesduvroq |
| Akebia Therapeutics INC | $152.36 | 2024 | Vafseo, Auryxia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $116.22 | 2025 | Symplicity G3 |
| Ani Pharmaceuticals, INC. | $115.35 | 2024-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $100.26 | 2019-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.24 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $88.67 | 2021-2023 | Lupkynis |
| Mallinckrodt Enterprises LLC | $45.12 | 2019 | |
| Lilly USA, LLC | $40.15 | 2025 | Jardiance |
| Novo Nordisk INC | $35.65 | 2025 | Ozempic, Rybelsus |
| Nxstage Medical, INC. | $34.66 | 2022-2023 | Liberty Select Cycler, Nxstage System One |
| Horizon Therapeutics Plc | $34.06 | 2023 | Krystexxa |
| Baxter Healthcare | $28.55 | 2020-2021 | |
| Pfizer INC. | $28.00 | 2024 | |
| Lundbeck LLC | $24.01 | 2019 | |
| Amicus Therapeutics, INC. | $19.94 | 2023 | Galafold |
| Daiichi Sankyo INC. | $19.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.93 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.68 | 2019 | |
| Kyowa Kirin, INC. | $13.24 | 2023 | |
| Cycle Pharmaceuticals INC | $13.24 | 2024 | Tiopronin |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smelser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.